Greenwood Capital Associates LLC Has $7.92 Million Stock Holdings in Johnson & Johnson $JNJ

Greenwood Capital Associates LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 51,821 shares of the company’s stock after selling 2,162 shares during the quarter. Johnson & Johnson accounts for 1.0% of Greenwood Capital Associates LLC’s investment portfolio, making the stock its 25th biggest position. Greenwood Capital Associates LLC’s holdings in Johnson & Johnson were worth $7,916,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $188.51 on Friday. The stock’s fifty day moving average price is $176.18 and its two-hundred day moving average price is $162.83. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. HSBC raised their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $188.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.